Med Discovery is a Swiss biopharmaceutical company dedicated to the discovery and the development of highly specific treatments for uro-genital cancers. Our strategy is to develop protein drugs based on the optimization of natural proteins involved in the regulation of biological pathways. To achieve this we are leveraging a unique in-house expertise in kallikreins, the biggest class of human proteases, combined with an international network in clinical urology. Our proprietary technology platform to produce protease inhibitors allows Med Discovery to target cancers or other diseases where there is a lack of specific treatment. Using this approach, Med Discovery intends to become a leading research and development biotech company in the uro-genital field, developing products both in-house and with appropriate partners.
